Translating 'Big Data' into Therapies, Diagnostics, and New Insights into Disease | GenomeWeb
May 24, 2016
Sponsored by
Abbott Informatics

Translating 'Big Data' into Therapies, Diagnostics, and New Insights into Disease


Director, Institute for Computational Health Sciences and Professor of Pediatrics, University of California, San Francisco & Executive Director for Clinical Informatics, University of California Health Sciences and Services

Manager, Global Strategy, Abbott Informatics

This webinar discussed how laboratory information management systems can help analyze big data in biomedicine in order to advance precision medicine.

There is an urgent need to take what we have learned in the “genome era” and use it to create a new system of precision medicine, delivering the best preventative or therapeutic intervention at the right time, for the right patients. Dr. Butte's lab at the University of California, San Francisco, builds and applies tools that convert trillions of points of molecular, clinical, and epidemiological data -- measured by researchers and clinicians over the past decade and now commonly termed “big data” -- into diagnostics, therapeutics, and new insights into disease.  Several of these methods or findings have been spun out into new biotechnology companies.  

Dr. Butte, a computer scientist and pediatrician, highlighted his lab’s recent work, including the use of publicly-available molecular measurements coupled with samples in public and private biorepositories and discovering new diagnostics including blood tests for complications during pregnancy. 

Learning Objectives

  • What is the nature of public molecular data?
  • How can publicly available molecular measurements be used to find new uses for drugs, or new diagnostics for diseases?
  • What is big data in biomedicine and how can we utilize a LIMS to analyze this data and help with diagnostics, prognostics and precision medicine?
  • How can we use samples in biorepositories to validate data-driven predictions and launch discoveries in novel diagnostics?

By registering for this webinar, you agree that the sponsor may contact you.

Sponsored by

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.